AIVITA Biomedical Nominated for 2026 Prix Galien USA Award
Nomination recognizes AIVITA’s personalized immunotherapy platform and its potential to advance cancer treatment and infectious-disease preparedness
AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, today announced that it has been named a 2026 Prix Galien USA nominee in the “Best Startup” category.
The Prix Galien USA Awards recognize exceptional scientific innovation with the potential to improve human health. Presented by The Galien Foundation, the Prix Galien is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research. Nominees for this year’s “Best Startup” category were selected following rigorous review. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.
“We are honored to be recognized by The Galien Foundation among an exceptional group of innovators,” said AIVITA CEO Dr. Hans S. Keirstead. “This nomination reflects the dedication of our team and the potential of our personalized dendritic-cell platform to address urgent unmet needs in cancer and infectious disease. Our goal is to make advanced, patient-specific immunotherapies practical, scalable and accessible to patients around the world.”
